<?xml version="1.0" encoding="UTF-8"?>
<p id="Par65">In summary, there are many ways to increase the immunogenicity of M2e. The most significant findings from preclinical studies of these universal vaccine prototypes are shown in TableÂ 
 <xref rid="Tab2" ref-type="table">2</xref>. However, their further use in clinical practice is limited by the lack of knowledge about the safety of the vectors for humans. Currently, the search for new carriers continues, in order to increase the immunogenicity of M2e, while new immunization strategies are also being sought, such as priming with live attenuated influenza virus, and boosting with M2e VLP [
 <xref ref-type="bibr" rid="CR73">73</xref>]. 
</p>
